Business leaders, entrepreneurs, residents, students — share your success! We’re collecting stories of the remarkable people, places, ideas and innovations that define the county in our video series, We Are Montgomery County.
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement to acquire the ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) business of Sanofi in an all-cash transaction with a total value of up to $125 million, consisting of $97.5 million upfront and up to $27.5 million in near-term contingent regulatory and manufacturing-related milestones.
Baltimore, Maryland-based Protenus, the company famously behind monthly Breach Barometers, is expanding its capabilities.
As part of a new effort, the organization will use its analytics platform to shed light on other problems in the world of healthcare. One example includes detecting suspected employee theft of prescription opiates.
QIAGEN (Suzhou) Translational Medicine, a China precision medicine company, raised $25 million in a Series A funding led by Qiming Venture Partners. QIAGEN (Suzhou) was founded in 2013 by QIAGEN, a global molecular diagnostics company headquartered in Germany, and BioBay, the Suzhou life science technology park. It specializes in developing biomarkers and stratifying patients in clinical trials. QIAGEN (Suzhou) said it plans to use the new capital to build a factory and expand its scientific team.
OpGen announced today that it has priced a previously announced $10 million public offering of 25 million units of common stock and common warrants at $.40 per unit.
SNNLive spoke with Richard Bendis, President and CEO of BioHealth Innovation, Inc., a private company, at the BioMaryland Pavilion at the BIO International Convention 2017 in San Diego, CA.
Southern Maryland Entrepreneurs / small business owners! Join SMIT and the Startup Maryland STRT1UP Roadshow to pitch your technology concept, prototype, product or service innovation.
Since 2012, Startup Maryland has roamed the state celebrating entrepreneurs and giving them the opportunity to video tape their pitch on the Startup Maryland STRT1UP Roadshow pitch bus. Here's how it works: Entrepreneurs register to pitch at https://startupmd.typeform.com/to/cMTP0f, then prepare and practice practice practice a 3 minute pitch. When the bus arrives, entrepreneurs enter the bus where a video studio has been set up to capture thier pitch. Pitches are then edited and ready for viewing! Pitches are judged by a panel of expert serial entrepreneurs, investors and economic development officers and compete for the opportunity to be selected to pitch at other state-wide events such as TEDCO's Annual Entrepreneur Expo and other prizes.
A new startup accelerator program based at the Johns Hopkins University’s FastForward East will target companies developing health and fitness technologies.
Hopkins is teaming up with the University of Maryland, Plank Industries, Brown Advisory and the Abell Foundation to launch the 16-week program, called M-1 Ventures, in September.
Who We Are
5 startups. 16 weeks. 1 mission.
M-1 Ventures is an accelerator for startups developing technologies that improve health outcomes, promote fitness and streamline health care. The program features mentorship from connected health and fitness experts at Johns Hopkins and the University of Maryland.
In monetary terms, D.C.’s tech scene has been doing pretty well with investors lately: Local start-ups took in about $435 million between April and June 2017, compared with $298 million over the same period four years ago, according to Pitchbook investment data analyzed by the National Venture Capital Association.
FDA and AACR have successfully held Oncology Dose Finding Workshops in 2015 and 2016. Patient and dose selection of oncology drugs will be of critical importance, as recent approvals of immune checkpoint inhibitors (ICIs) and early, promising readouts from studies combining ICIs with chemotherapy, targeted therapy, and other immuno-oncology agents will put enormous pressures on the current clinical trial infrastructure of the U.S. and the international community. A recent article in The Cancer Letter reported that 803 clinical trials currently testing PD-1 and PD-L1 drugs had over 160,000 slots for adult patients. As more ICIs enter the market, additional trials will seek to combine these products with standard of care therapies, novel small molecules, targeted antibodies, and other biologic therapies such as vaccines and engineered T-cells. This year’s workshop will focus on approaches to combination therapy and best practices regarding patient and dose selection, biomarkers to aid in selection, and novel endpoints that can define patient benefit.
Join BioBuzz and sponsor Immunomic Therapeutics to celebrate the move from allergy to oncology application of their proprietary LAMP-Vax™ technology platform. The celebration will be at Bar Louie in the Rockville Town Center on July 27, 2017 from 5 - 7pm. Only a 5 minute walk from the Rockville Metro, please join us for this exciting event.
A Brooklyn-based biotech company was awarded $32.3 million in incentives over 10 years from the state’s Economic Development Authority to move its headquarters to the 116-acre former Hoffmann-La Roche North American headquarters campus on the border of Nutley and Clifton.
The US National Institutes of Health (NIH) would see its budget rise by US$1.1 billion in 2018, to $35.2 billion, under a spending proposal released on 12 July by lawmakers in the House of Representatives.
A Food and Drug Administration panel opened a new era in medicine on Wednesday, unanimously recommending that the agency approve the first-ever treatment that genetically alters a patient’s own cells to fight cancer, transforming them into what scientists call “a living drug” that powerfully bolsters the immune system to shut down the disease.
The world's top medical technology companies are turning to robots to help with complex knee surgery, promising quicker procedures and better results in operations that often leave patients dissatisfied. Demand for artificial replacement joints is growing fast, as baby boomers' knees and hips wear out, but for the past 15 years rival firms have failed to deliver a technological advance to gain them significant market share.
The 17th annual New York Venture Summit, presented by youngStartup Ventures, is the premier industry gathering connecting venture capitalists, corporate VCs, angel investors, technology transfer professionals, senior executives of early stage and emerging growth companies, university researchers, incubators and premier service providers.
Whether you are an investor seeking access to new early stage deals, or a CEO or Founder of a new venture looking for funding, visibility and growth, New York Venture Summit is one event you won’t want to miss.
This isn’t your ordinary health care discussion. Quality Talks is a series of stirring, succinct talks by current and emerging health care leaders with ideas about how we can collaboratively improve American health care. In addition to the dynamic and thought-provoking speakers, the event features interactive dialogue among all attendees about advancing the health care system and improving patient care.
Quality Talks began in 2015 as part of NCQA’s 25th Anniversary and grew so successfully that NCQA made it an annual event. In 2016, this sold-out event was held at a larger venue which enabled us to reach an even wider audience. We hope to continue in 2017 with thought-provoking speakers and continuing the Quality Talks health care discussion.
Yesterday, the White House announced it was delaying and likely eliminating the International Entrepreneur Rule. This rule is the closest we’ve come to a Startup Visa, something I’ve been working on with numerous other people since 2009. Several failed bills in Congress, a failed bipartisan Senate comprehensive immigration reform bill, and an Executive Order later, and we still have nothing.
Patient outcomes are taking over from products and services as the focus of healthcare. But reorienting away from product development toward a holistic approach to patients demands the convergence of data from every part of the healthcare system. In this interview, part of our Biopharma Frontiers series on how the pharmaceutical industry is evolving, Jared Josleyn, global head of corporate development at Alphabet-owned Verily Life Sciences, talks with McKinsey’s Michele Raviscioni about the need to integrate health data and apply it to patients’ lives in ways that achieve enduring impact.
